Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Joao Carrasco"'
Autor:
Robert P. Finger, Vincent Daien, Bora M. Eldem, James S. Talks, Jean-Francois Korobelnik, Paul Mitchell, Taiji Sakamoto, Tien Yin Wong, Krystallia Pantiri, Joao Carrasco
Publikováno v:
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Systematically review the evidence describing the impact of anti–vascular endothelial growth factor (anti-VEGF) therapy on neovascular age-related macular degeneration (nAMD) patient outcomes and healthcare resource utilization.
Externí odkaz:
https://doaj.org/article/f45d0f99ce8940e7bba288dcf781e693
Autor:
Vincent Daien, Bora M. Eldem, James S. Talks, Jean-Francois Korobelnik, Paul Mitchell, Robert P. Finger, Taiji Sakamoto, Tien Yin Wong, Obaro Evuarherhe, Gemma Carter, Joao Carrasco
Publikováno v:
BMC Ophthalmology, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational studi
Externí odkaz:
https://doaj.org/article/48ff1ba02ceb49afb884803c81dd7d53
Publikováno v:
Ophthalmology and Therapy
Background The 96 weeks’ assessment from the VIEW studies provided insights into the long-term efficacy of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD) and demonstrated that it was possible to maintain l
Autor:
Oliver Will, Yusuke Hikichi, Koji Tanaka, Takeshi Joko, Yoshimi Nagai, Yuji Oshima, Martine C Maculaitis, Ryusaburo Mori, Kanji Takahashi, Joao Carrasco, Tetsushi Komori, Kathleen Beusterien
Publikováno v:
Patient preference and adherence
Takeshi Joko,1 Yoshimi Nagai,2 Ryusaburo Mori,3 Koji Tanaka,3 Yuji Oshima,4 Yusuke Hikichi,5 Tetsushi Komori,6 Joao Carrasco,7 Martine C Maculaitis,8 Oliver Will,8 Kathleen Beusterien,8 Kanji Takahashi2 1Department of Ophthalmology, Matsuyama Red Cro
Autor:
Craig Bennison, Jisu Yoon, Georg-Alexander Pietsch, Marie-Pierre Nicolas, Cecile Koerber, Joao Carrasco
Publikováno v:
Advances in Therapy
Introduction Treatment of neovascular age-related macular degeneration (nAMD) has evolved with the advent of anti-vascular endothelial growth factor agents such that intravitreally administered aflibercept and ranibizumab (RBZ) have become the standa
Autor:
Finger, Robert P., Daien, Vincent, Eldem, Bora M., Talks, James S., Jean-Francois Korobelnik, Mitchell, Paul, Sakamoto, Taiji, Wong, Tien Yin, Pantiri, Krystallia, Joao Carrasco
Additional file 1: Table 1. Study eligibility criteria.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a22020d5b5e09231092875651a46433
Autor:
James S Talks, Jean-François Korobelnik, Krystallia Pantiri, Bora Eldem, Taiji Sakamoto, Joao Carrasco, Vincent Daien, Robert Finger, Tien Yin Wong, Paul Mitchell
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, BioMed Central, 2020, 20, pp.294. ⟨10.1186/s12886-020-01554-2⟩
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-14 (2020)
BMC Ophthalmology, BioMed Central, 2020, 20, pp.294. ⟨10.1186/s12886-020-01554-2⟩
BMC Ophthalmology, Vol 20, Iss 1, Pp 1-14 (2020)
Background Systematically review the evidence describing the impact of anti–vascular endothelial growth factor (anti-VEGF) therapy on neovascular age-related macular degeneration (nAMD) patient outcomes and healthcare resource utilization. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815de84525afe7cdc398751bcb8c39e4
https://hal.archives-ouvertes.fr/hal-03120124/file/BPH_BMCO_2020_Finger.pdf
https://hal.archives-ouvertes.fr/hal-03120124/file/BPH_BMCO_2020_Finger.pdf
Autor:
Paul Mitchell, Obaro Evuarherhe, Gemma Carter, Jean-François Korobelnik, James S Talks, Taiji Sakamoto, Robert Finger, Tien Yin Wong, Vincent Daien, Bora Eldem, Joao Carrasco
Publikováno v:
BMC Ophthalmology
BMC Ophthalmology, BioMed Central, 2019, 19 (1), ⟨10.1186/s12886-019-1208-9⟩
BMC Ophthalmology, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Ophthalmology, 2019, 19 (1), ⟨10.1186/s12886-019-1208-9⟩
BMC Ophthalmology, BioMed Central, 2019, 19 (1), ⟨10.1186/s12886-019-1208-9⟩
BMC Ophthalmology, Vol 19, Iss 1, Pp 1-12 (2019)
BMC Ophthalmology, 2019, 19 (1), ⟨10.1186/s12886-019-1208-9⟩
Background Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational studies and pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb39af8a2055a46844de8d16c2f60be5
https://hal.umontpellier.fr/hal-02555353/document
https://hal.umontpellier.fr/hal-02555353/document
Autor:
Daien, Vincent, Eldem, Bora, Talks, James, Jean-Francois Korobelnik, Mitchell, Paul, Finger, Robert, Sakamoto, Taiji, Wong, Tien, Obaro Evuarherhe, Carter, Gemma, Joao Carrasco
Table S1. Data sources and accessibility. (DOCX 32 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3abf704c30c1155953f38fd048a5f2e
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 8, Iss 3, Pp 15-23 (2016)
Objective: This analysis aims to estimate the cost-effectiveness of early treatment versus delayed treatment with fingolimod 0.5 mg/day in patients with relapsing-remitting multiple sclerosis. Study Type: Economic evaluation of health technologies
Externí odkaz:
https://doaj.org/article/9795372ea4154ef280c1dcda7008d5b9